News Hub | News Direct

News Release

Stem Cell Stocks on the Rise: Companies Driving the $48 Billion Market Boom

ADIA FATE DNA PLUR

The stem cell and regenerative medicine sector is experiencing a wave of innovation, driven by cutting-edge technologies and an expanding range of applications across healthcare, biotechnology, and even food security. With the potential to revolutionize treatments for conditions like Alzheimer’s, autoimmune disorders, and cancer, stem cell therapies are unlocking new possibilities for regenerative medicine. Advances in iPSC (induced pluripotent stem cells), umbilical cord stem cells, and 3D cell-based platforms are fueling this growth, while increasing demand for affordable and accessible treatments is pushing the market forward. Valued at over $15 billion, the global stem cell market is projected to reach USD 48.83 billion by 2034, registering a CAGR of 11.3% from 2024 to 2034. This remarkable growth reflects the sector’s potential as breakthroughs in research translate into real-world applications. From therapies that harness the body’s own healing mechanisms to scalable solutions addressing global challenges, the opportunities for innovation and investment are immense. Now, let’s explore four stocks making waves in this dynamic and transformative sector. Adia Nutrition Inc. (OTC Pink: ADIA) is making significant strides in the $15.1 billion global stem cell market with its innovative approach to regenerative medicine. The company operates two key divisions: Adia Labs, which provides premium organic supplements, and Adia Med, its medical division specializing in advanced stem cell therapies such as Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT). By focusing on affordability and accessibility, Adia Nutrition is positioning itself as a leader in the rapidly expanding field of regenerative medicine. On March 17, 2025, Adia Med announced that all future full-service clinic locations across the U.S. will offer Therapeutic Plasma Exchange (TPE), a cutting-edge procedure that removes harmful substances from the bloodstream. Already available at the company’s Winter Park, Florida clinic, TPE has shown promise in treating Alzheimer’s disease, autoimmune disorders, and even complications from COVID-19. The treatment utilizes the same advanced apheresis machines used in Hematopoietic Stem Cell Transplantation (HSCT), reinforcing Adia Med’s commitment to leveraging state-of-the-art medical technology. Earlier in March, Adia Labs reached a major milestone with the FDA registration of Adia Vita, its premier stem cell product. Each unit contains 100 million viable cells and 3 trillion exosomes, offering a powerful and cost-effective solution in regenerative medicine. This FDA registration enables Adia Labs to distribute Adia Vita nationwide, expanding access to cutting-edge stem cell therapies for doctors and clinics across the country. With traditional stem cell treatments often costing between $15,000 and $35,000 per procedure, Adia Med stands out by offering high-quality therapies at more affordable rates, fueling rapid client growth. Adia Nutrition’s growth trajectory in 2025 has been marked by several key corporate advancements. In February, the company took steps to strengthen its financial and operational foundation by retiring 25 million undocumented shares, successfully removing its shell risk designation, and launching Adia Labs LLC. These strategic moves not only reinforce investor confidence but also set the stage for an OTCQB uplisting, which will enhance the company’s market visibility and liquidity. To accelerate its expansion, Adia Med is forming partnerships with elite Medical Spas, establishing satellite locations that provide a scalable and low-risk model for nationwide growth. With over 4.5 million Florida residents aged 65 and older, Adia Med is uniquely positioned to address a significant demand for age-related treatments, particularly for conditions like Alzheimer’s and autoimmune disorders. With the expansion of TPE, the nationwide rollout of Adia Vita, and the impending OTCQB uplisting, ADIA is entering a phase of rapid growth. As Adia Nutrition Inc. (OTC: ADIA) continues to scale operations and push the boundaries of regenerative medicine, it is well-positioned to deliver innovative healthcare solutions while generating value for investors, making it a stock to keep an eye on. Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company specializing in iPSC-derived cellular immunotherapies. The company’s proprietary platform creates engineered iPSC lines for off-the-shelf T-cell and NK-cell products, targeting diseases in autoimmunity and oncology. Fate’s lead program, FT819, is an iPSC-derived CAR T-cell therapy for systemic lupus erythematosus (SLE), now in Phase 1 trials. Recent dose-expansion data from SLE patients show promising results, including no significant toxicities and one patient achieving clinical remission. The company is also exploring FT819’s potential in other autoimmune diseases. Fate’s FT825 CAR T-cell therapy targets solid tumors and is being tested in combination with monoclonal antibodies in collaboration with Ono Pharmaceutical. Early data show favorable safety and cellular activity. The company’s FT522 CAR NK cell therapy for B-cell lymphoma is progressing, with the added advantage of not requiring conditioning chemotherapy, thanks to its Alloimmune Defense Receptor (ADR) technology. FT522 is also being evaluated for autoimmune conditions. With $307 million in cash, Fate is well-funded through 2026, allowing it to advance these promising therapies. As the company pushes forward in clinical trials, Fate Therapeutics stands out in the growing field of off-the-shelf stem cell-based treatments with significant growth potential. Ginkgo Bioworks (NYSE: DNA) is a leading cell programming platform, offering end-to-end solutions across industries like food, agriculture, pharmaceuticals, and biosecurity. Their biosecurity division focuses on next-generation infrastructure to help detect and respond to biological threats. In Q4 2024, Ginkgo reported total revenue of $44 million, up 26% from the previous year. This growth was driven by a 29% increase in cell engineering revenue, which reached $35 million. Biosecurity revenue grew modestly to $9 million, reflecting an evolving business model. For the full year, Ginkgo posted $227 million in revenue, down 10% due to the transition in their biosecurity business and a shift in focus toward larger customers in cell engineering. Despite the dip in overall revenue, Ginkgo reduced its GAAP net loss significantly, reporting $547 million, compared to $893 million in 2023. Their adjusted EBITDA loss also improved, dropping from $365 million to $293 million. The company ended 2024 with $562 million in cash, positioning them well to execute their strategy. Strategically, Ginkgo has made notable strides in cell engineering, with 31 new customer programs added in Q4 2024. They also signed a key contract with a top biopharmaceutical company for their antibody developability product. Their Ginkgcellutomation division was selected for a $9.4 million project with Carnegie Mellon to develop bioelectronic devices. Looking ahead, Ginkgo aims to reach adjusted EBITDA breakeven by 2026 and has targeted $250 million in cost reductions by Q3 2025. For 2025, Ginkgo projects $160-$180 million in total revenue, with $110-$130 million expected from Cell Engineering and at least $50 million from Biosecurity. With a strong cash position and clear cost-cutting initiatives, Ginkgo is poised for sustainable growth, particularly in its core cell engineering and biosecurity sectors. Pluri Inc. (Nasdaq: PLUR) stands out in the crowded biotech and stem cell sectors due to its innovative approach to leveraging its proprietary 3D cell-based technology platform. Unlike many other companies that primarily focus on regenerative medicine, Pluri is expanding its impact into areas like foodtech and agtech, making it a versatile and dynamic player. Its cutting-edge technology addresses a wide range of global challenges, from medical advancements to food security and sustainability. By offering scalable, cost-effective, and consistent cell production, Pluri is positioning itself as a leader in creating next-generation solutions for some of the world’s most pressing issues. What really sets Pluri apart is its unique capability to apply its cell-based technology across diverse industries. For example, the company is taking a significant leap into the food industry by partnering with Kokomodo Ltd., an AgTech company focused on cultivated cacao. This move aligns Pluri with the rapidly growing demand for sustainable food production and plant-based alternatives. By acquiring a 71% stake in Kokomodo, Pluri is expanding its reach into the cultivated cacao market, which is expected to grow significantly in the coming years. The deal not only positions Pluri to tap into the billion-dollar cacao market but also showcases its ability to diversify into unconventional applications for cell-based technologies. Moreover, Pluri is expanding its role in global crisis response through its collaboration with Hemafund Ltd. to address the potential need for countermeasures against radiation exposure in Ukraine. The collaboration aims to produce and stockpile PLX-R18, a cell therapy designed to treat Hematopoietic Acute Radiation Syndrome (H-ARS), which could be crucial in the event of nuclear threats. This kind of forward-thinking approach, combining biotech innovation with real-world emergency preparedness, shows Pluri's broader vision for applying its technology to urgent global health needs, making it more than just another biotech company in a competitive market. The company’s recent $6.5 million investment and acquisition announcements reinforce its commitment to growth and innovation. These moves position Pluri not only as a major player in regenerative medicine and cell-based therapies but as a company with the flexibility and vision to push the boundaries of what biotech can achieve across different sectors. By aligning itself with other industries, such as food production and emergency preparedness, Pluri has shown that it is not just riding trends in the biotech space, but rather, shaping the future of multiple industries with its versatile, scalable technologies. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ADIA Nutrition Inc. to assist in the production and distribution of this content related to ADIA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com

March 18, 2025 07:00 AM Eastern Daylight Time

Centre For Neuro Skills to Open Clinic in Plano; Fifth in Texas

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a premier provider of treatment for traumatic and acquired brain injury, today announced the opening of its new clinic in Plano, Texas. CNS’ approximately 20,000 square ft. facility at 1649 Dallas Parkway will open to new patients in winter 2025-2026. “Over the past few years, we’ve seen population growth in the North Dallas area, with Plano being one of the fastest growing regions,” said David Harrington, CEO of CNS. “We are increasing our footprint in Texas to meet the high demand for our facilities and individualized services to bring high-quality post-acute care to not only North Texas but also neighboring states like Oklahoma.” Patient-centered approach to treating brain injury CNS, highly regarded for its expertise in brain injury and stroke treatment as well as its experienced staff. Three of CNS’ clinics, including one in Irving, recently received accreditation by the Behavioral Health Center of Excellence for demonstrating its commitment to the standards of excellence for applied behavior analysis services. As CNS’ fifth Texas location, the Plano clinic will deepen the post-acute care provider’s commitment to the Dallas Healthcare community and the state. CNS’ Plano location’s many advanced-care features include: Programs for vision, neurobehavior, cognitive retraining, speech, physical and occupational therapy provided by highly trained and certified clinical therapy staff The ZeroG® Gait and Balance System Bioness Integrated Therapy System (BITS), used to aid in vision, motor and balance training Individualized counseling as well as family counseling (a hallmark of CNS support) Opportunities to participate in cutting edge brain injury and stroke research Brain injury and its devastating and costly effects Traumatic brain injury (TBI) is caused by blunt, traumatic forces to the brain. Acquired Brain Injury (ABI) is a non-traumatic brain injury or disease such as stroke, encephalitis or other infectious diseases, anoxic/hypoxic injury (lack of oxygen to the brain), aneurysms, seizure disorders, surgical procedures and toxic exposure. According to the Brain Injury Association of America, 2.9 million Americans visit the emergency department due to a TBI every year. According to the Texas Brain Injury Alliance: 144,000 Texans sustain a TBI each year — one every 4 minutes More than 381,000 Texans live with a disability due to a TBI — 2% of the population More than 5,700 Texas residents are permanently disabled by TBI each year Convenient Location CNS’ new clinic offers space to accommodate a broader population of inpatient, outpatient, day treatment and residential post-acute brain injury patients. It is adjacent to the Dallas North Tollway and located minutes from area airports and hotels. *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

March 13, 2025 08:01 AM Pacific Daylight Time

Spring Bird Welcomes Thomas Hoskins as New Director of Operations

Spring Bird

Spring Bird, a leading provider of innovative transit solutions, is pleased to announce the appointment of Thomas Hoskins as its new Director of Operations. With more than two decades of experience in transit operations, fleet management, and manufacturing process improvement, Thomas will play a critical role in optimizing Spring Bird’s operational strategy and driving continued growth. Thomas brings a wealth of expertise to his new role, having served eight years as Director of Operations at Complete Coach Works, where he led fleet modernization efforts and oversaw large-scale production improvements. His career also includes 13 years as an Operations Manager at Motor Coach Industries, where he gained extensive experience managing complex transit manufacturing and service operations. “Spring Bird is growing rapidly, and having an experienced, forward-thinking leader like Thomas at the helm of our operations is part of our long-term growth strategy,” said Elliott Carson, CEO and Founder of Spring Bird. “Tom’s history of driving efficiency and innovation aligns perfectly with our mission to provide safe, high-quality transit solutions. We are excited for his leadership and enhance will drive our operational excellence and benefit our customers.” In his new role, Thomas will oversee production processes, fleet operations, and strategic planning, ensuring that Spring Bird continues to meet and exceed industry standards. His leadership will support the company’s ongoing efforts to expand its offerings, enhance efficiency, and deliver reliable, sustainable transit solutions. “I am honored to join Spring Bird at such a pivotal time in its growth,” said Thomas Hoskins, Director of Operations. “The company’s commitment to quality, innovation, and customer service is truly inspiring. I look forward to working with the team to refine processes, improve efficiency, and continue delivering exceptional transit solutions that keep our customers moving.” Spring Bird, founded in 2020, builds upon the Carson family’s decades-long legacy in the transit industry, offering a wide range of heavy-duty transit buses and rehabilitation services. The company services the industry's top operators, providing buses for sale and lease, and specializes in minor repairs, major overhauls, and operational maintenance solutions. With Thomas at the helm of operations, Spring Bird is well-positioned to continue its expansion and commitment to excellence in transit solutions. About Spring Bird Spring Bird is a premier provider of transportation solutions, specializing in the sale, leasing, and service of heavy-duty transit buses and motor coaches. Drawing from the rich Carson family legacy in the transportation industry, Spring Bird offers an inventory of high-quality buses from leading manufacturers and provides customized rehabilitation services, including minor repairs, major overhauls, and technological retrofitting. Dedicated to safety, innovation, and customer satisfaction, Spring Bird addresses the unique needs of cities, transit agencies, and private operators, ensuring reliable and efficient transportation solutions. Media Contact: For more information, visit https://springbirdbus.com or contact us at press@springbirdbus.com. ### About Spring BirdSpring Bird is a premier provider of transportation solutions specializing in the sale, leasing, and service of heavy-duty transit buses and motor coaches. Drawing from the rich Carson family legacy in the transportation industry, Spring Bird offers an inventory of high-quality buses from leading manufacturers and provides customized rehabilitation services, including minor repairs, major overhauls, and technological retrofitting. Dedicated to safety, innovation, and customer satisfaction, Spring Bird addresses the unique needs of cities, transit agencies, and private operators, ensuring reliable and efficient transportation solutions. Contact Details Media Contact press@springbirdbus.com Company Website https://springbirdbus.com

March 12, 2025 09:00 AM Central Daylight Time

Image

Centre for Neuro Skills Launches its First Advertising Campaign

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a leader in traumatic brain injury and stroke rehabilitation services, has launched the company’s first advertising campaign in its 45-year history. The initial campaign, “Rethink Rehab,” is aimed at medical decision-makers, prospective patients and their families and will roll out across video digital platforms, social media and out-of-home advertising, bringing a fresh and engaging message to consumers. Designed to raise awareness of the CNS brand, its services and its impact, the campaign features dramatic, dark visuals that end on an inspiring note of hope for all that are recovering from brain injury or stroke. The campaign’s theme, “Rethink Rehab,” captures the essence of CNS’ mission to reduce disability and maximize independence, reinforcing its commitment to achieve the maximum quality of life for patients through brain injury rehabilitation. "With 'Rethink Rehab,' we’re redefining how we connect with our audience,” said Ben Ashley, Associate Vice President Marketing and Communications for CNS. "Through this multichannel campaign, we aim to raise awareness of the CNS brand, our services, and our impact within both professional and cultural contexts. We recognize that our audience is diverse and that our influence extends to medical decisions, countless patients and their families. Our ultimate goal is to increase access to our care by spreading knowledge about CNS, even before it is needed. This campaign embodies our brand’s passion for neurorehabilitation and brings it to life in an authentic, compelling way.” CNS employs a unique and individualized treatment approach that is transforming the understanding of effective neurorehabilitation programs for individuals recovering from brain injury and stroke. The creative agency behind the campaign is Moon Rabbit, an independent advertising agency with offices in New York, California and London. Their clients range from boutique to blue-chip and from consumer to biotech. CNS’ partnership with Moon Rabbit has enabled them to highlight this impact through a 30-second spot. The video begins with an inspiring journey of a mother as she perseveres through her brain injury recovery. It concludes on a positive note as she successfully regains control of her daily tasks and family life. Throughout her journey, our experienced and compassionate staff are there to guide her every step of the way. “‘Neurorehabilitation’ is a word only learned after a life gets fundamentally shaken. And yet, too often, the conversation in this space can feel detached & mechanical,” said John Tenaglia, Managing Partner, Client Services at Moon Rabbit. “Just as CNS brings humanity to their process, we aim to bring humanity to the conversation around what rehabilitation & recovery really look like.” This short film is just one component of our exciting new multichannel advertising campaign with Moon Rabbit, which includes digital banners, out-of-home promotions, social media placements, radio spots, and published advertorials. Key highlights of the campaign include: Multi-Platform Reach – The campaign will launch across social media, digital streaming, and radio and unique activations. Engaging Storytelling – The video begins with an inspiring journey of a mother as she perseveres through her brain injury recovery. It concludes on a positive note as she successfully regains control of her daily tasks and family life. Throughout her journey, our experienced and compassionate staff are there to guide her every step of the way. The campaign officially debuted on February 1, 2025. Consumers can follow the conversation using #[RethinkRehab] and view campaign content at www.neuroskills.com, Facebook, Twitter, LinkedIn or YouTube. For media inquiries, interviews, images or additional information, please contact: Robin Carr Landis Communications Inc. 415.766.0927 CNS@landispr.com *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

March 10, 2025 08:01 AM Pacific Daylight Time

Image

Centre for Neuro Skills Launches the “Neuro Skills Podcast,” Focused on Brain Injury Rehabilitation

Centre for Neuro Skills

The Centre for Neuro Skills (CNS) has launched the “Neuro Skills Podcast,” a new series that delves into the latest trends, research and inspiring stories behind the transformative power of brain injury rehabilitation. Debuting on YouTube and Spotify on Monday, March 3, in recognition of Brain Injury Awareness Month, this weekly video series features real-life recovery stories and expert insights on cutting-edge brain injury therapies. The podcast aims to deepen understanding of brain injury rehabilitation and its life-changing possibilities. Hosted by CNS CEO and President David Harrington—a licensed occupational therapist and Certified Brain Injury Specialist with more than 30 years of experience—the podcast will feature conversations with industry leaders, brain injury survivors and experts in post-acute rehabilitation. Notable guests include CNS founder Dr. Mark Ashley and key figures in neurorehabilitation, who will share their expertise and personal experiences. “Brain injury rehabilitation is a journey of resilience, innovation and hope. Through the ‘Neuro Skills Podcast,’ we aim to shed light on groundbreaking therapies, share real recovery stories and provide valuable insights from experts in the field,” says David Harrington, President and CEO of Centre for Neuro Skills and podcast host. “Our goal is to empower patients, families and healthcare professionals with the knowledge and inspiration they need to navigate the path to healing.” Episodes: Episode 1 (available now): A Place of Healing: The Story of CNS When Dr. Mark Ashley’s brother, Steve, became disabled after a devastating event in 1972, conventional rehabilitation therapy gave no hope for recovery. Dr. Ashley, Founder of CNS, made it his mission to find a way for Steve to regain his independence through post-acute rehabilitative care. His recovery became the model for CNS’ ongoing philosophy of practice and our belief that patients don’t plateau, and every brain injury survivor deserves a place to heal and regain independence. Episode 2 (March 10, 2025): Heart Health is Brain Health Pt. 1 Most people don’t know that strokes are brain injuries. This episode explores the connection between heart health and brain health – an often-overlooked aspect of stroke prevention and recovery. Tune in as David Harrington, President and Chief Executive Officer of CNS, and Chris Persel, Regional Director of Clinical Services, Director of Behavior Programming at CNS, dive into key statistics, discuss stroke prevention methods, and explain treatment options that help stroke survivors rebuild their lives and regain independence. Episode 3 (March 17, 2025): Heart Health is Brain Health Pt. 2 Recovery from a brain injury is a lifelong personal journey. David Harrington, President and Chief Executive Officer of CNS, and Chris Persel, Regional Director of Clinical Services, Director of Behavior Programming at CNS, continue their discussion on the importance of engaging patients in rehabilitation through individualized treatments and enriched environments. Episode 4 (March 24): Resilience and Renewal After a Brain Injury How do emotions impact recovery? David Harrington, President and Chief Executive Officer of CNS, and Dr. Gary Seale, Regional Director of Clinical Services at CNS, talk about the significant role that positive emotions play in patient recovery. This episode explores the benefits of being in a positive emotional state: ability to process information quickly and accurately, boost to the immune system, and there’s a less likely chance to trigger the flight or fight response that can lead to risk factors for stroke. Episode 5 (March 31): A Doctor Becomes the Patient: Stroke Survivor Story An unexpected stroke not only impacted Dr. Petersen’s motor skills, but it also changed the way he views the patient experience. A loving father with a background in pediatric emergency medicine, Dr. Petersen overcame physical, emotional, and cognitive deficits during his stroke rehabilitation journey, finding a renewed sense of purpose when he returned to work. In this episode, Dr. Petersen shares his journey from physician to patient and sheds light on the transformative power of rehabilitation. Produced in collaboration with the American Heart Association (AHA) as part of its “Live Fierce campaign,” the “Neuro Skills Podcast” reflects CNS’s commitment to advancing neurorehabilitation and heart health. Through this partnership, CNS and the AHA aim to provide critical information to stroke patients and the broader community, reinforcing the connection between brain health and cardiovascular well-being. *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

March 06, 2025 08:01 AM Pacific Standard Time

Image

Bacula Systems Announces Direct Integration with ZFS for Enhanced Backup and Recovery Performance

Bacula Systems

Bacula Systems, a global leader in high-security, high-performance backup and recovery solutions, today announced its latest Use Case: native integration and interoperability with the ZFS file system. This latest enhancement empowers organizations with seamless, high-performance backup and recovery capabilities specifically optimized for ZFS-based infrastructures. The integration of ZFS into Bacula Enterprise enables enterprises and high-performance computing (HPC) environments to take full advantage of ZFS’s advanced storage management features while leveraging Bacula’s robust, scalable, and highly secure backup and disaster recovery capabilities. “Bacula continues to set the standard for reliability, security, and exceptionally high performance in backup and recovery, and our new native ZFS integration further expands our customers’ ability to protect and manage their data in the most efficient way possible. By enabling seamless, high-speed backup and reliable restore operations for ZFS environments, Bacula helps organizations reduce complexity, improve storage efficiency, and maintain strict security and compliance requirements. This is one of a series of important announcements we are making in the high performance file systems space” said Frank Barker, CEO of Bacula Systems. Key Benefits of Bacula’s ZFS Integration: Snapshot-Based Backups: Bacula leverages ZFS snapshots to enable efficient, low-latency backups without impacting system performance. Speed: Bacula’s ZFS capabilities include a fast incremental accelerator for massive file systems and big data volume - all done automatically. Workload Efficiency: Bacula integrates with ZFS's diff feature to quickly backup only necessary/modified files, without needing to scan the entire file system. Advanced Data Protection: Bacula complements its ZFS capabilities with configurable compression, checksum verification, advanced encryption technology, comprehensive ransomware protection, air-gapped architectures, highly flexible immutable storage options and many other highly customizable data protection features for compliance-driven industries. Seamless Scalability: Optimized for large-scale environments, Bacula’s ZFS integration provides ultra-fast backup of snapshot differences of massive datasets. Cost-Efficiency: Organizations can significantly lower their storage costs by leveraging Bacula’s advanced deduplication and compression capabilities in conjunction with Bacula’s efficient data management features. Bacula Systems continues to expand its leadership in providing powerful, customizable, and highly secure backup and recovery solutions tailored for enterprises and HPC environments. The addition of built-in ZFS interoperability underscores Bacula’s commitment to delivering high-performance, flexible, and cost-effective data protection for IT teams managing large and complex workloads. Bacula Systems customers include NASA, Navisite, Texas A&M University, Sky PLC, Warner Bros Discovery, Locaweb and many more. For more information about Bacula’s ZFS integration and enterprise backup solutions, visit www.baculasystems.com. About Bacula Systems: Bacula Enterprise is an exceptionally secure, highly scalable backup and recovery software for large organizations, data centers and MSPs. www.baculasystems.com Contact Details Rob Morrison rob.morrison@baculasystems.com +41 21 641 60 80 rob.morrison@baculasystems.com Company Website https://www.baculasystems.com/

March 05, 2025 07:11 AM Eastern Standard Time

News Release

The Future of Stem Cell Investing: Spotlight on Smaller Innovators

ADIA BLUE CRSP MESO

The global stem cell therapy market is entering an era of unprecedented growth and innovation. Valued at $5.13 billion in 2024, the U.S. stem cell market alone is projected to reach $15.79 billion by 2034, growing at a compound annual growth rate (CAGR) of 11.9%. Globally, the market is expected to hit $28.89 billion by 2030, fueled by advancements in regenerative medicine, increased government funding for research, and the development of groundbreaking therapies for conditions like cancer, autoimmune diseases, and genetic disorders. Stem cells, often called the body’s internal repair system, have the unique ability to divide and regenerate, offering hope for treatments that address the root causes of diseases rather than just managing symptoms. From repairing damaged tissues to regenerating organs, the potential applications of stem cell therapies are vast and transformative. The U.S. Food and Drug Administration (FDA) has already approved several stem cell-based treatments, and the pipeline of new therapies continues to expand. This rapid growth is driven by several key factors: the rise of stem cell banks, increasing therapeutic potential, and a surge in research aimed at developing regenerative medicines. While large pharmaceutical companies and research institutions play a significant role, smaller biotech firms are also making important contributions, pushing the boundaries of what’s possible in this dynamic field. In this piece, we explore some of the companies making waves in this exciting and rapidly evolving sector, highlighting their achievements, challenges, and potential to shape the future of medicine. ADIA Nutrition Inc. (OTC: ADIA) is on a mission to transform healthcare through innovation in regenerative medicine and premium organic supplements. Operating under two key divisions—its supplement arm and Adia Med, its medical division—the company is making waves in the fast growing global stem cell market. With cutting-edge therapies like Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT), ADIA Nutrition is empowering patients to address conditions ranging from autoimmune disorders to orthopedic injuries. 2025 has been a landmark year for ADIA Nutrition, with groundbreaking achievements that emphasize innovation and accessibility. In March, the company celebrated the FDA registration of Adia Vita, its premier stem cell product. This allows Adia Vita to be distributed nationwide, significantly expanding access to regenerative medicine. "This acceptance reflects Adia Labs' commitment to broadening access," said Larry Powalisz, CEO of ADIA Nutrition. The registration enhances patient access and opens new revenue opportunities. In February, ADIA announced a strategic expansion plan by partnering with elite Medical Spas to create satellite locations across the U.S. This low-cost model will offer treatments like UCB-SC therapies and stem cell injectables to health-conscious regions, tapping into an existing customer base and creating revenue streams via service fees, royalties, and equity interests. "This expansion is a testament to our commitment to making therapies more accessible," Powalisz said. The launch of Adia Labs LLC in February solidified ADIA’s leadership in regenerative medicine. Adia Labs introduced AdiaVita, a high-potency stem cell product containing 100 million cells and 3 trillion exosomes per dose, designed for clinical research and therapeutic use. A future product, AdiaLink, will contain 3.5 trillion exosomes, pushing the boundaries of medical science. "We are advancing medical science while maintaining the highest standards of safety and quality," Powalisz stated. A key to ADIA’s success is its partnership with a premier FDA-approved laboratory, ensuring the highest quality stem cell and exosome products. Each dose is third-party verified for purity, potency, and safety, making it a trusted choice for medical professionals. "After months of due diligence, we offer the best quality therapies per treatment," Powalisz noted. This partnership guarantees a steady supply of top-tier products. ADIA is also working to secure private insurance coverage for treatments like aHSCT and injectable stem cells, reducing the financial burden on patients and expanding access. "Registering with the AHCA is a monumental step in providing open access to our therapies," Powalisz said. The company’s integration into the mainstream healthcare ecosystem is gaining traction, with several patients already preapproved by private insurers. The Winter Park, Florida clinic has exceeded financial expectations in its first month of operation, offering FDA-compliant treatments for conditions like Multiple Sclerosis, hip issues, and joint pain. "Many patients have traveled abroad for treatments we now offer locally," said Dr. Monica Sher, Chief Stem Cell Medical Officer at Adia Med. Looking ahead, ADIA plans to replicate its successful clinic model in new markets, expand satellite locations, and complete its uplisting to the OTCQB Venture Market. With aspirations for a Nasdaq listing, the company could be poised for significant growth. "From January's financial win to February's breakthroughs, we’re redefining healthcare possibilities," Powalisz added. "We’re committed to innovation and sustainable growth." For investors, ADIA offers a unique opportunity to be part of a company revolutionizing healthcare. With its innovative treatments, strategic partnerships, and commitment to quality, ADIA Nutrition is well-positioned to lead the regenerative medicine industry. CRISPR Therapeutics (NASDAQ: CRSP) is a biotechnology company that uses the CRISPR/Cas9 gene-editing tool to develop treatments for serious diseases. This powerful technology, which won a Nobel Prize, enables scientists to modify faulty genes that cause a variety of illnesses. The company made a major breakthrough in late 2023 when its first product, CASGEVY, became the first-ever CRISPR-based therapy to gain FDA approval. CASGEVY targets two blood disorders—sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)—by utilizing stem cells, marking a significant milestone in the practical application of gene editing. The launch of CASGEVY has been progressing well. By the end of 2024, over 50 treatment centers globally were set up to administer the therapy, and more than 50 patients had already begun the treatment process. The company anticipates further growth in patient enrollment in 2025, with clinical trials for children aged 5 to 11 now completed, with results expected later this year. In addition to CASGEVY, CRISPR Therapeutics is exploring ways to improve stem cell therapies, including developing methods that avoid the need for intensive pre-treatment steps. While the company is initially known for its blood disorder treatments, CRISPR Therapeutics is expanding its focus to other areas, such as cancer and autoimmune diseases. One promising program is CTX112, an advanced CAR T-cell therapy that uses modified immune cells to fight blood cancers. Early results from clinical trials have been promising, and the FDA has granted CTX112 a special designation to expedite its development. Updates on CTX112’s progress are expected in mid-2025. CRISPR is also investigating the potential of CTX112 in treating autoimmune diseases, such as lupus, with more data anticipated in the coming months. CRISPR Therapeutics (NASDAQ: CRSP) is also looking into regenerative medicine, with one of its key initiatives, CTX211, aiming to treat Type 1 diabetes using stem cells. The goal is to enable patients to produce their own insulin, potentially eliminating the need for daily injections or long-term medication. Additional information on this program is expected in 2025. Financially, CRISPR Therapeutics is in a strong position, with approximately $1.9 billion in cash, providing a solid foundation for continued research and development. While CASGEVY’s sales may face slow growth due to the complex nature of the treatment process, the company remains focused on long-term goals, developing transformative therapies that could significantly impact patients’ lives. Despite challenges in the stock market, many analysts maintain an optimistic outlook for CRISPR Therapeutics. Some predict a potential 87% increase in its stock price within the next 12 months, especially if upcoming clinical trial results prove positive. With its innovative technology, diverse therapeutic pipeline, and solid financial backing, CRISPR Therapeutics (NASDAQ: CRSP) is well-positioned to remain a leader in gene editing and stem cell therapies. Mesoblast Limited (NASDAQ: MESO) is a biotech company focused on developing stem cell-based treatments for severe inflammatory diseases. One of its major advancements is RYONCIL, a mesenchymal stromal cell (MSC) therapy that received FDA approval in December 2024. RYONCIL is designed to treat steroid-refractory acute graft-versus-host disease (SR-aGvHD), a life-threatening condition in which a patient's immune system attacks the body after a bone marrow transplant. In clinical trials, RYONCIL demonstrated a 70% response rate, with 49% of patients surviving for four years. The therapy is priced at $194,000 per infusion and is available through Mesoblast’s MyMesoblast patient services hub, with distribution managed by Cencora. Mesoblast is also expanding the use of its stem cell technology for other conditions. The company is testing RYONCIL in pediatric patients with Crohn’s disease, a severe inflammatory bowel disease. Early studies in adults have shown promising results, and Mesoblast plans to extend testing to children who have not responded to other treatments. Additionally, Mesoblast is developing REVASCOR, a stem cell therapy aimed at treating heart failure. In 2024, the FDA supported an accelerated approval pathway for REVASCOR in patients with end-stage heart failure who rely on mechanical heart pumps. Mesoblast is also researching REVASCOR for children with hypoplastic left heart syndrome (HLHS), a rare heart condition, which could open the door to further FDA approvals. On the financial front, Mesoblast is in a relatively strong position. The company raised $161 million in a private placement, leaving it with approximately $200 million in cash to support its ongoing research and development activities. Mesoblast has also reduced its operating expenses by 22% from the previous year, indicating improved financial management. With the FDA-approved RYONCIL and a pipeline of other promising therapies, Mesoblast appears positioned to continue its work in stem cell-based treatments. bluebird bio, Inc. (NASDAQ: BLUE), founded in 2010, has been a significant player in the field of gene therapy, focusing on developing treatments for severe genetic diseases like sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. Over the years, the company has received FDA approvals for three gene therapies, positioning itself as a leader in the space. However, despite its scientific accomplishments, bluebird bio has faced substantial financial challenges, leading to its decision to go private in 2025. In early 2025, bluebird bio announced an agreement to be acquired by global investment firms Carlyle Group Inc. and SK Capital Partners, along with a team of biotech executives. Under the terms of the deal, bluebird bio’s stockholders will receive $3.00 per share in cash, with the potential for additional payouts of up to $9.84 per share through a contingent value right, depending on the performance of its product portfolio. The acquisition, expected to close in the first half of 2025, will provide bluebird bio with the capital needed to scale the commercial delivery of its gene therapies. "For more than a decade, bluebird has been at the forefront of gene therapy, delivering treatments to patients facing life-threatening genetic diseases," said Andrew Obenshain, CEO of bluebird bio. "However, as financial challenges mounted, it became clear that securing the right strategic partner was critical to maximizing value for our stockholders and ensuring the long-term future of our therapies." The acquisition arrives at a difficult time for bluebird bio. The company has faced mounting financial pressures, including the denial of a priority review voucher by the FDA and the risk of loan default. By partnering with Carlyle and SK Capital, bluebird bio aims to secure the necessary resources to continue its operations and bring its therapies to patients. Upon completion of the deal, bluebird bio will no longer be publicly traded, and former Mirati Therapeutics CEO David Meek is expected to take over as the new CEO. bluebird bio has achieved notable scientific milestones, particularly with its LYFGENIA (lovotibeglogene autotemcel, or lovo-cel) gene therapy for sickle cell disease. At the 66th American Society of Hematology (ASH) Annual Meeting in December 2024, the company presented long-term data showing that LYFGENIA significantly reduces or eliminates vaso-occlusive events (VOEs) in patients with sickle cell disease. Among the 58 patients treated in the HGB-206 and HGB-210 studies, 94.7% achieved complete resolution of severe VOEs, with benefits sustained for a median of over four years. Notably, patients with a history of overt stroke, a severe complication of sickle cell disease, remained stable without recurrent strokes for up to nine years post-treatment. These results highlight the therapy's potential to address the underlying cause of the disease. Despite these scientific successes, bluebird bio’s financial struggles highlight the challenges of commercializing high-cost gene therapies, particularly in a complex reimbursement environment. The decision to go private reflects the difficulties in balancing innovation with financial sustainability. While its shares will soon be removed from public trading, bluebird bio’s contributions to the field of gene therapy remain significant. Its therapies have provided new treatment options for patients with severe genetic conditions, and its ongoing research continues to advance gene therapy science. As the company transitions to private ownership, its focus on delivering innovative treatments to patients will remain central to its mission. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ADIA Nutrition Inc. to assist in the production and distribution of this content related to ADIA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com

March 04, 2025 07:00 AM Eastern Standard Time

ASSOCIATION OF PICKLEBALL PLAYERS ANNOUNCES APP NATIONAL PICKLEBALL CHALLENGE SUPPORTING THE AMERICAN CANCER SOCIETY

Association of Pickleball Players

The Association of Pickleball Players (APP) and the American Cancer Society will join forces during National Pickleball Month this April to launch the APP National Pickleball Challenge, a nationwide initiative designed to support people facing cancer and build healthier communities. The APP National Pickleball Challenge tasks participants to play pickleball ten times during the month and track their active minutes, competing for a spot atop the national leaderboard. Whether it’s playing a competitive match, enjoying a casual match with friends, cardio training, or bouncing a ball up and down on a paddle, any pickleball-related activity will count towards the challenge. Players can register and start fundraising today on JustGiving and will start tracking their pickleball activity on April 1 via the Stridekick mobile application or manually. “We are excited to work with the American Cancer Society to continue to use pickleball for good,” said Shannon Dan, APP EVP of Strategy and Growth. “By participating in this challenge, you can play the sport you love, reduce your personal cancer risk by staying active, and support people facing cancer. It’s such a fun, easy way to make a difference!” One hundred percent of the proceeds raised during the APP National Pickleball Challenge will directly benefit the American Cancer Society and their mission through funding cancer research discoveries, enhancing direct patient support in 20,000 communities across the country and through advocating for policies that enhance access to cancer care. How It Works Sign Up: Beginning Wednesday, Feb. 26, register for the APP National Pickleball Challenge on JustGiving. Start fundraising! All challengers that generate $25 in donations will receive a free “Strength & Hope” t-shirt from the American Cancer Society and the top ten fundraisers will receive a revolutionary OWL Sport paddle from the APP! Grab your paddle and get moving! Once the challenge is live, you can easily track your activity and compete with friends using the Stridekick mobile app. It even allows you to connect your fitness tracker and work your way up the national leaderboard for active minutes. Spread the word about the APP National Pickleball Challenge and share updates on your progress throughout the month on social media to spark more donations! The American Cancer Society is a leading cancer-fighting organization with a vision to end cancer as we know it, for everyone. For more than 110 years, the organization has been improving the lives of people with cancer and their families as the only organization combating cancer through advocacy, research, and patient support. To learn more about the APP National Pickleball Challenge and support the American Cancer Society, visit cancer.org. The pickleball community can stay in the know on the latest APP updates at theapp.global, and by following the APP’s Instagram, X, Threads, TikTok, Facebook and LinkedIn channels. The Association of Pickleball Players (APP) provides opportunities for pickleball players of all ages and skill levels—professionals, amateurs and recreational—to compete in world-class pickleball events for the opportunity to win prize money and be featured on nationally televised broadcasts on CBS Sports and ESPN. Since its launch in 2019, the APP has operated the first and only pro and amateur pickleball tour fully and officially sanctioned by USA Pickleball. The APP opened its official headquarters and player development center in January 2025 at The Fort in Fort Lauderdale, Fla., while its corporate offices continue to be located in Chicago. The APP Tour’s 2025 schedule will feature the most robust pickleball showcase across pro and amateur competitions accompanied by youth development programs, grassroots charity initiatives and international partnerships to continue to grow the game. Schedules, recent news and additional information about the APP are available at theapp.global and on Instagram, X, Threads, TikTok, Facebook and LinkedIn. Contact Details Daniel Sagerman +1 847-800-8182 dsagerman@theapp.global Company Website https://www.theapp.global

February 27, 2025 12:00 PM Eastern Standard Time

News Release

Spin-Offs: Potential Catalysts for Big Gains

OSTX MMM K GE

Spin-offs can be powerful catalysts for unlocking shareholder value by transforming distinct business units into standalone entities. This separation often creates growth opportunities and attracts investor interest, potentially leading to significant price gains and the allure of stock dividends. Let’s explore recent examples of completed spin-offs, examine how they have shaped the market, and highlight a potential opportunity to keep an eye on. OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company focused on innovative cancer treatments, recently announced a strategic move that could significantly enhance shareholder value: the formation of its subsidiary, OS Drug Conjugates (OSDC), and plans to spin off joint ventures (JVs) into standalone public companies. This initiative, coupled with the potential for stock dividends, has, in some cases, driven increased investor interest and share price appreciation, making OSTX a compelling opportunity. On February 20, 2025, OS Therapies unveiled its plan to spin off its next-generation tunable Antibody Drug Conjugate (tADC) and tunable Drug Conjugate (tDC) platforms into standalone entities through JVs with clinical-stage ADC therapeutics companies. These platforms, which use proprietary silicon-based linkers (SiLinkers™) to deliver targeted cancer therapies, are part of a rapidly growing market projected to reach $47 billion by 2029. The company intends to distribute stock dividends of these public JVs to shareholders, a move that could unlock hidden value and provide investors with direct exposure to high-growth segments. Spin-offs often create value by allowing investors to more clearly evaluate the worth of distinct business units. In OS Therapies’ case, the tADC and tDC platforms represent cutting-edge technology with significant potential in oncology. By spinning off these assets into standalone entities, OS Therapies could attract specialized investors and partnerships, further accelerating development and commercialization. Additionally, the spin-off dividend structure provides shareholders with tangible returns, enhancing the appeal of OSTX as an investment. While the spin-off is a key catalyst, OS Therapies’ core value driver remains its lead asset, OST-HER2, an immunotherapy targeting HER2-positive cancers. The company recently reported positive Phase 2b trial results for OST-HER2 in recurrent osteosarcoma, achieving its primary endpoint with statistical significance. The data showed: 33% of OST-HER2 patients were responders vs. 11% in the matched historical control group. 91% survival rate at 12 months vs. 80% in the control group. A strong safety profile supporting regulatory approval. OS Therapies is preparing to submit a Biologics Licensing Application (BLA) to the FDA in 2025, with potential approval by late 2025. If approved, OST-HER2 would be the first new treatment for osteosarcoma in over 40 years, addressing a $500 million market opportunity. The company also stands to receive a Priority Review Voucher (PRV), which it could sell for an estimated $150 million, providing non-dilutive capital to fund further development. OS Therapies is well-capitalized, with a $13.1 million cash position following a recent financing round. The company has also acquired new clinical assets to expand its pipeline, further solidifying its position in the oncology space. With a strong financial position, innovative technology platforms, and a clear path to market, OSTX presents a unique investment opportunity in the rapidly growing oncology sector. General Electric (NYSE: GE), a storied industrial conglomerate, made headlines on April 2, 2024, when it completed the tax-free spin-off of its power business into GE Vernova (GEV). Investors received 1 share of GEV for every 4 shares of GE owned, a move that has since proven to be a significant value driver for shareholders. Since the spin-off, GEV has performed remarkably well, opening at $142.85, briefly selling off, and then rallying to trade above $160 per share. With a market cap of $47 billion and an enterprise value of $41 billion, GE Vernova is now a standalone leader in the global energy sector. The spin-off allowed the market to focus on the growth potential of GE Vernova’s three core segments: Power (55% of revenue), Wind (22% of revenue), and Electrification (23% of revenue). The Electrification segment, in particular, has emerged as a standout, with a growing backlog and expanding margins driven by volume and price increases. This segment is expected to deliver strong revenue growth and continued margin expansion beyond 2024, supported by operational improvements and increasing demand for grid solutions. The Wind segment, while showing improvement in 2024, faces challenges such as lower equipment orders and EBITDA losses in Offshore Winds. Meanwhile, the Power segment remains resilient but may struggle to match the growth trajectory of Electrification. Despite these mixed dynamics, GE Vernova’s diversified portfolio positions it well to capitalize on the global energy transition. GE Vernova’s mission—embedded in its name—reflects its commitment to innovation and sustainability. The “GE” legacy signifies quality and ingenuity, while “Vernova” (from “verde” and “nova”) underscores its focus on a new era of lower-carbon energy. The company is uniquely positioned to benefit from the increasing demand for power generation and grid electrification, particularly in the U.S., where infrastructure investments are accelerating. Management expects GE Vernova to generate $36 billion in revenue in 2025, with $1.5 billion in free cash flow. These projections highlight the company’s strong financial foundation and its ability to deliver value to shareholders. Since its debut, GE Vernova has defied initial skepticism, rallying above $160 per share after opening at $142.85. This performance underscores the market’s confidence in the spin-off’s potential to create value. Historically, spin-offs like GEV have driven aggressive price gains as investors gain clarity on the standalone business’s growth prospects and financials. GE Vernova’s early success suggests it could follow a similar trajectory, particularly as it leverages its leadership in electrification and power generation. 3M (NYSE: MMM), the global science and innovation company behind iconic brands like Post-it notes, Scotch tape, and Thinsulate insulation, has been on a transformative journey. On April 1, 2024, 3M completed the tax-free spin-off of its healthcare division into Solventum (SOLV), a standalone company focused on advancing healthcare through breakthrough solutions at the intersection of health, material, and data science. Investors received 1 share of Solventum for every 4 shares of 3M owned, and the spin-off has been a significant catalyst for 3M’s stock, which has surged 89.3% over the past year, far outpacing the S&P 500’s 34.8% return. The spin-off allows 3M to focus on its core industrial and consumer products businesses, which include a diverse portfolio of over 55,000 products. By separating its healthcare division, 3M has unlocked value for shareholders, enabling both companies to pursue their distinct growth strategies. Solventum, now a standalone entity, specializes in products that treat and prevent infections, dental filling materials, and filtration and purification systems. The new company is well-positioned to capitalize on the growing demand for innovative healthcare solutions, while 3M can concentrate on driving innovation in its industrial and consumer segments. 3M retained a 19.9% stake in Solventum but plans to divest its remaining shares within five years, providing additional liquidity and potential upside for shareholders. The spin-off was structured as a tax-free transaction, further enhancing its appeal to investors. Additionally, 3M recently reached a significant milestone with the approval of its $10.3 billion settlement related to “forever chemicals” (PFAS) litigation. This resolution removes a major overhang for the company and provides greater clarity for its future growth trajectory. Since its debut, Solventum has entered the S&P 500 and begun trading on the New York Stock Exchange, reflecting its strong market position and growth potential. The company’s focus on enabling better, smarter, and safer healthcare aligns with global trends toward improved patient outcomes and more efficient healthcare systems. The spin-off of Solventum has been a win-win for 3M and its shareholders. By unlocking the value of its healthcare division, 3M has streamlined its operations and positioned itself for sustained growth in its core markets. Meanwhile, Solventum’s focus on healthcare innovation offers significant upside potential. Together, these developments have driven 3M’s stock to impressive gains, making it a standout example of how spin-offs can create value for investors. Kellanova (NYSE: K) completed a major restructuring, spinning off its North American cereal business into a new entity named WK Kellogg Co (NYSE: KLG) last year. This move created two independent, publicly traded companies: Kellanova (K) on the New York Stock Exchange, which focuses on global snacking, international cereal and noodles, and North American frozen foods, and WK Kellogg Co (KLG), also trading on the New York Stock Exchange, which concentrates on ready-to-eat cereals in the U.S., Canada, and the Caribbean. Shareholders of the original Kellogg Company received 1 share of WK Kellogg Co for every 4 shares of Kellanova common stock they owned, marking the beginning of a new chapter for both companies. Kellanova, which retained the iconic ticker symbol “K,” is now a pure-play snacking powerhouse with a portfolio of beloved brands like Pringles, Cheez-Its, Rice Krispies Treats, and more. The spin-off allows Kellanova to focus on its core strengths in the global snacking market, which is growing rapidly as consumer preferences shift toward convenient, on-the-go foods.” WK Kellogg Co, is now dedicated to revitalizing its North American cereal business, a segment that has faced challenges in recent years due to changing breakfast habits and increased competition. By separating the cereal business, both companies can operate more efficiently and pursue tailored growth strategies. Following the spin-off, both Kellanova and WK Kellogg Co experienced initial declines in their stock prices, with Kellanova falling over 7% and WK Kellogg Co dropping about 5% on the first day of trading. However, the long-term success of each company will depend on their ability to execute their respective strategies and adapt to evolving market conditions. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by O S Therapies Inc to assist in the production and distribution of content related to OSTX. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com

February 27, 2025 07:00 AM Eastern Standard Time